ACT invests in Glakolens, a university spin-off developing a contact lens based biosensor technologies.

Glakolens was founded by the members of a research group at Boğaziçi University and led by Prof. Günhan Dündar, Dr. Arda Deniz Yalçınkaya and Dr. Hamdi Torun. Glakolens’ first product is a novel non-invasive continuous intra-ocular pressure (IOP) diagnostics and monitoring device based on proprietary technology licensed from Boğaziçi University. The company’s strategy is to focus on introducing a product to address specific needs in ophthalmology where there is need for viable products.

Glaucoma affects 70 million people worldwide, a chronic condition with no cure and the second leading cause of blindness. Glaucoma causes damage to the eye’s optic nerve and gets worse over time. It is often associated with a build-up of pressure inside the eye. This increased pressure, called intraocular pressure, can damage the optic nerve, which transmits images to the brain. Without treatment, glaucoma can cause total permanent blindness within a few years. Most people with glaucoma have no early symptoms or pain from increased IOP and IOP fluctuates during the day, so the only viable approach to preventing blindness is to carefully diagnose and monitor IOP over a period and design a therapeutic strategy to minimize further damage to the optic nerve. Loss of vision caused by glaucoma is irreversible and cannot be restored with available methods.

However, successfully monitoring IOP cycles and lowering eye pressure can help prevent further visual loss from glaucoma. Current IOP monitoring technologies have demonstrated limited efficacy, accuracy or patient comfort. The IOP sensor developed by Glakolens is based on a novel non-invasive approach to very accurately diagnose and passively monitor fluctuations in IOP by measuring certain properties of the eye. The data is collected comfortably and wirelessly over a period without going to the hospital and further processed using various protocols to offer insight on IOP. Glakolens is a more effective non-invasive, wireless, and comfortable IOP monitoring system allowing an accurate characterization of the IOP profile of a wide range of patients.

The founders of Glakolens have been developing biosensor technologies since 2010 and developed a core competency around contact lens based biosensors. They have also been working on novel biosensors that can identify biomarkers over skin for the diagnosis of several diseases simultaneously.

ACT made a seed investment of EUR 465.000 to Glakolens. The company will focus on further refining, testing, and certification of the technology with ACT’s investment.

Further information will soon be available at:

www.glakolens.com

info@glakolens.com